These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1488 related articles for article (PubMed ID: 18226324)

  • 1. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
    Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
    Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report of implant placement in a patient with Paget's disease on bisphosphonate therapy.
    Pirih FQ; Zablotsky M; Cordell K; McCauley LK
    J Mich Dent Assoc; 2009 May; 91(5):38-43. PubMed ID: 19537656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paget disease of bone - an update.
    Britton C; Walsh J
    Aust Fam Physician; 2012 Mar; 41(3):100-3. PubMed ID: 22396921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paget's disease of bone.
    Siris ES
    J Bone Miner Res; 1998 Jul; 13(7):1061-5. PubMed ID: 9661069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.